However, there is a need for further preclinical studies, including overexpressing or silencing INVS and its related genes/proteins in renal cancer cells, applying immunotherapy to establish possible effects depending on the expression of INVS, and performing later clinical studies. This evidence concerns the gene INVS and renal carcinoma.